These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16467761)

  • 21. Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer.
    Faraj K; Chang YH; Rose KM; Habermann EB; Etzioni DA; Blodgett G; Castle EP; Humphreys MR; Tyson Ii MD
    Can J Urol; 2019 Oct; 26(5):9922-9930. PubMed ID: 31629441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.
    Tolley DA; Parmar MK; Grigor KM; Lallemand G; Benyon LL; Fellows J; Freedman LS; Grigor KM; Hall RR; Hargreave TB; Munson K; Newling DW; Richards B; Robinson MR; Rose MB; Smith PH; Williams JL; Whelan P
    J Urol; 1996 Apr; 155(4):1233-8. PubMed ID: 8632538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group.
    Bouffioux C; Kurth KH; Bono A; Oosterlinck W; Kruger CB; De Pauw M; Sylvester R
    J Urol; 1995 Mar; 153(3 Pt 2):934-41. PubMed ID: 7853578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy: Electromotive mitomycin in superficial bladder cancer.
    Oosterlinck W
    Nat Rev Clin Oncol; 2011 Sep; 8(11):633-4. PubMed ID: 21912417
    [No Abstract]   [Full Text] [Related]  

  • 26. Single instillation of mitomycin C reduces 1st year recurrence following transurethral resection of non-muscle invasive bladder cancer.
    Ather MH; Aziz S; Sulaiman MN
    J Ayub Med Coll Abbottabad; 2007; 19(4):18-20. PubMed ID: 18693589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study.
    Kondás J; Kiss L; Határ A; Kiss A; Lukács T; Szeldeli P; Törzsök F; Bodrogi I
    Int Urol Nephrol; 1999; 31(4):451-6. PubMed ID: 10668939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
    Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
    J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of patients with superficial transitional cell carcinoma of the urinary bladder treated by intravesical mitomycin C.
    Pavlotsky A; Eidelman A; Barak F; Walach N; Horn Y
    J Surg Oncol; 1995 Nov; 60(3):191-5. PubMed ID: 7475070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
    Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
    Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.
    Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
    Eur Urol; 2012 Nov; 62(5):797-802. PubMed ID: 22633362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.
    Paroni R; Salonia A; Lev A; Da Pozzo LF; Cighetti G; Montorsi F; Rigatti P; Colombo R
    Br J Clin Pharmacol; 2001 Sep; 52(3):273-8. PubMed ID: 11560559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.
    Au JL; Badalament RA; Wientjes MG; Young DC; Warner JA; Venema PL; Pollifrone DL; Harbrecht JD; Chin JL; Lerner SP; Miles BJ;
    J Natl Cancer Inst; 2001 Apr; 93(8):597-604. PubMed ID: 11309436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-C.
    Lenis AT; Asanad K; Blaibel M; Donin NM; Chamie K
    BMC Urol; 2018 Oct; 18(1):93. PubMed ID: 30355350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Oral tegafur plus mitomycin versus intravesical mitomycin alone in the prevention of recurrence in stage Ta bladder tumors].
    Server Pastor G; Rigabert Montiel M; Bañón Pérez V; Valdelvira Nadal P; Cao Avellaneda E; García Hernández JA; Pérez Albacete M
    Actas Urol Esp; 2003 Jun; 27(6):438-41. PubMed ID: 12918150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients.
    Milla P; Fiorito C; Soria F; Arpicco S; Cattel L; Gontero P
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):503-9. PubMed ID: 24442034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up.
    El-Ghobashy S; El-Leithy TR; Roshdy MM; El-Ganzoury HM
    J Egypt Natl Canc Inst; 2007 Jun; 19(2):121-6. PubMed ID: 19034342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group.
    Ryoji O; Toma H; Nakazawa H; Goya N; Okumura T; Sonoda T; Kihara T; Tanabe K; Onizuka S; Tomoe H
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S60-4. PubMed ID: 7994789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitomycin C for the treatment of bladder cancer.
    Volpe A; Racioppi M; D'Agostino D; Cappa E; Filianoti A; Bassi PF
    Minerva Urol Nefrol; 2010 Jun; 62(2):133-44. PubMed ID: 20562793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
    Hausladen DA; Wheeler MA; Altieri DC; Colberg JW; Weiss RM
    J Urol; 2003 Jul; 170(1):230-4. PubMed ID: 12796695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.